舒心饮改善气阴两虚型胸痹患者中医证候的疗效分析

目的观察舒心饮改善气阴两虚型胸痹(冠心病心绞痛)患者中医证候的疗效。方法将胸痹患者133例随机分为治疗组(66例)与对照组(67例)。治疗组予舒心饮治疗,对照组予生脉饮治疗,疗程共4周。主要观察治疗前后患者中医证候疗效情况。结果治疗后,两组患者的胸闷、头晕、失眠、心悸等中医证候均获得改善,治疗组对胸闷和失眠的改善明显优于对照组(P<0.01)。结论较经典益气养阴药物生脉饮而言,舒心饮能够更好地改善胸痹患者胸闷和失眠中医证候;气阴两虚     

舒心饮改善气阴两虚型胸痹患者中医证候的疗效分析

目的:探讨舒心饮改善气阴两虚型胸痹(冠心病心绞痛)患者中医证候的疗效分析。方法:将胸痹患者133例随机分为治疗组66例与对照组67例。治疗组选用舒心饮治疗,对照组选用生脉饮治疗,疗程均为4周。主要观察治疗前后患者中医证候疗效情况。结果:经治疗两组患者的胸闷、头晕、失眠、心悸等中医证候均获得改善,舒心饮对胸闷和失眠的改善明显优于对照组(p<0.05或p<0.01)。结论:较经典益气养阴药物生脉饮而言,舒心饮能够更好的改善胸痹患者胸闷和失眠中医证候。     

Effect of Shuxinyin (舒心饮) on In-Stent Restenosis after Coronary Artery Stenting

Objective: To evaluate the effect of anti-platelet regimens and it's combination with Shuxinyin (SXY, 舒心饮,) on in-stent restenosis after stent implantation. Methods: Forty-four patients with successful stent implantation in a coronary artery were randomly assigned to the treated group (n=20) and the control group (n=24). The treated group received: SXY and anti-platelet therapy. The control group were treated with anti-platelet regimens only. Platelet activation was assessed before and immediately after the stenting by flow cytometry, the expression of P-selectin (CD62P) and glycoprotein(GP) Ⅱb/Ⅲa receptor. It was reassessed on the 30th day after stenting. Plasma fibrinogen (Fg) and C-reaction protein (CRP) were measured by biuret and laser scattering turbidimetry respectively at the same time. Observation was made on the scoring of the symptoms of Qi deficiency syndrome, Qi-Yin deficiency syndrome and blood stasis syndrome in the two groups. Differences between groups were compared. Results: Compared with the control group, combination with SXY and anti-platelet therapy was remarkable in reducing plasma CRP (P<0.05), and also with the tendency to decrease plasma Fg, GPⅡb/Ⅲa and CD62P. It could also evidently decrease the scoring of Qi-Yin deficiency syndrome, Qi deficiency syndrome and blood stasis syndrome after stenting (P<0.05, 0.01, 0.01) respectively. Follow-up survey found 40% relapse of angina pectoris with 4 cases of in-stent restenosis proved by angiography in the treated group. But the relapse of angina pectoris in the control group was 67% with 2 cases of myocardial infarction (MI), 7 cases of in-stent restenosis proved by angiography and one death. Conclusions: Combination with SXY and anti-platelet regimens can prevent stent thrombosis and in-stent restenosis after stent implantation, and it seems superior to anti-platelet therapy only.     

天花粉蛋白终止妊娠的因素分析

本文根据581例中期妊娠天花粉蛋白引产的资料,对影响引产时间和副反应等有关因素,采用逐步回归法借助于微电脑作了多变量分析。结果:引产时间与年龄、孕月呈正相关,与出血量、血红蛋白、给药途径呈负相关,与剂量、胎次、副反应无相关;出血量与胎次、孕月、用药剂量、血红蛋白呈正相关,与引产时间呈负相关。用药后最高体温与用药后心率、皮疹呈正相关,与红细胞数、给药途径呈负相关。对皮疹、血压、心率也作了相关分析。对它们的相互关系结合临床作了初步探讨。     

肺结核23例近期疗效观察

前言肺结核是严重的慢性传染病之一,发病率高,影响劳动力大,自连霉素、对氨柳酸、异菸肼、氨硫脲等抗痨药物应用以来,预后已大见改善.但是,这些药物也有一定的缺点,如抗药性的易于产生、药物的副作用及过敏性反应等,此     

支气管哮喘50例临床分析

支气管哮喘至今还是难于防治的、反复发作性疾病之一。现将我院二年来的住院病例以中医治疗为主的50例分析如下:病例来源及诊断标准本组病例,均为来院急诊、经初步诊为支气管哮喘而收住入院的患者。入院后,由中西医共同诊断,确诊为本病,作为分析对象。诊断标准的依据为:1)具有典型的发作史、过敏史及家庭史;2)显著的发作症状及哮鸣音;3)X 线透视及全身体检,摒除因其他原因而引起的哮喘性疾病;4)血常规及痰液检查,嗜酸性细胞增加,除外其他原因者。     

林钟香教授治疗心病验案2则

林钟香教授是上海中医药大学附属龙华医院心内科主任医师，博士生导师，业医50载，医术精湛，学验俱丰，收效良多。笔者有幸随师临证，受益颇多，现将其治疗心病验案2则介绍如下。     

舒心祛风汤对冠心病心绞痛患者血sICAM-1、sVCAM-1和MCP-1的影响

目的观察舒心祛风汤治疗冠心病心绞痛的临床疗效,探讨其作用机制。方法将86例患者随机分为治疗1组(29例)、治疗2组(29例)和对照组(28例)。治疗1组予西医常规治疗加舒心祛风汤,治疗2组予西医常规治疗加舒心饮,对照组予西医常规治疗。各组均治疗1个月,观察心绞痛疗效、中医证候疗效、心电图疗效及治疗后血sICAM-1、sVCAM-1和MCP-1水平的变化情况。结果治疗1组心绞痛疗效、心电图疗效、中医证候疗效均优于对照组(P<0.05,P<0.01);治疗1组sICAM-1、sVCAM-1与MCP-1水平均显著降低,与对照组比较,差异有统计学意义(P<0.05,P<0.01);且治疗1组sVCAM-1水平低于治疗2组,差异有统计学意义(P<0.05)。结论祛风舒心汤治疗冠心病心绞痛疗效确切,其机制可能与抑制炎症反应有关。     

舒心饮与血府逐瘀汤对不同证型冠心病心绞痛患者血小板活化相关因子的影响

目的:比较益气养阴方舒心饮和活血化瘀方血府逐瘀汤治疗冠心病心绞痛的疗效,并以血小板活化指标为切入点探讨证型与疗效的关系.方法:采用区组随机、单盲、平行对照试验方法,将94例气虚血瘀型及心血瘀阻型的冠心病心绞痛患者随机分为2组,其中舒心饮组49例,血府逐瘀汤组45例.疗程1个月.观察治疗前后患者心绞痛临床疗效和血小板活化指标.结果:舒心饮和血府逐瘀汤均在心绞痛疗效、心电图疗效、中医胸痹证候总疗效抑制血小板活化方面有显著疗效;方证对应组疗效更佳.结论:胸痹治疗的临床疗效与方证对应密切相关,血小板活化指标可能是反映方证对应程度的中药作用靶点.